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With no approved pharmacological treatment, nonalcoholic fatty liver disease (NAFLD) is
now the most common cause of chronic liver disease in Western countries and its worldwide
prevalence continues to increase along with the growing obesity epidemic. Here, we show that
a high-fat high-sucrose (HFHS) diet, eliciting chronic hepatosteatosis resembling human fatty
liver, lowers hepatic nicotinamide adenine dinucleotide (NAD1) levels driving reductions in
hepatic mitochondrial content, function, and adenosine triphosphate (ATP) levels, in con-
junction with robust increases in hepatic weight, lipid content, and peroxidation in C57BL/6J
mice. To assess the effect of NAD1 repletion on the development of steatosis inmice, nicotina-
mide riboside, a precursor of NAD1 biosynthesis, was added to the HFHS diet, either as a pre-
ventive strategy or as a therapeutic intervention. We demonstrate that NR prevents and reverts
NAFLD by inducing a sirtuin (SIRT)1- and SIRT3-dependent mitochondrial unfolded pro-
tein response, triggering an adaptive mitohormetic pathway to increase hepatic b-oxidation
and mitochondrial complex content and activity. The cell-autonomous beneficial component
of NR treatment was revealed in liver-specific Sirt1 knockout mice (Sirt1hep2/2), whereas apo-
lipoprotein E-deficient mice (Apoe2/2) challenged with a high-fat high-cholesterol diet
affirmed the use of NR in other independent models of NAFLD. Conclusion: Our data war-
rant the future evaluation of NAD1 boosting strategies to manage the development or pro-
gression of NAFLD. (HEPATOLOGY 2015; 00:000-000)
N
onalcoholic fatty liver disease (NAFLD)
encompasses a disease spectrum that can pro-
gress from hepatic steatosis to nonalcoholic
steatohepatitis (NASH), fibrosis, and, finally, cirrhosis1
and is projected to become the most common indication
leading to liver transplantation in the United States by
2030.2 Unfortunately, there are few existing therapies
for NAFLD and NASH,3,4 which are also suboptimal,
hence the urge to find new preventive and therapeutic
strategies to manage these chronic hepatic diseases. Often,
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alterations in lipid homeostasis, associated with obesity or
insulin resistance, result in the increase of lipolysis in fat
and delivery of free fatty acids to the liver, favoring
hepatic lipogenesis.5 In addition, incomplete fatty acid
(FA) oxidation in the context of mitochondrial dysfunc-
tion can also contribute to hepatic FA and lipid overload
(reviewed in a previous study6). With prolonged exis-
tence, these alterations in lipid homeostasis can promote
oxidative stress and lipid peroxidation (LPO) in the liver,
leading to elevated cytokine production, inflammation,
and fibrosis. It is this distinction that divides the appear-
ance of a fatty liver with that of the appearance of NASH
and, eventually, hepatocellular carcinoma.7,8 Because gen-
eration of oxidative stress is one of the key mediators of
this disease, the pursuit of treatments to improve the dys-
functional state of liver mitochondria has become a prime
goal to alleviate the pathophysiology of NASH.
Recent evidence demonstrates that nicotinamide ade-
nine dinucleotide (NAD1) repletion protects organisms
from metabolic diseases, induced by genetic factors,
diet, or aging.9-14 These findings corroborate the role of
sirtuins, many of which rely on NAD1 as a cosubstrate,
in eliciting metabolic improvements in various tissues
(reviewed in a previous study15). However, despite the
rapidly advancing field, the role of NAD1 in the devel-
opment and protection from NAFLD is still unspeci-
fied. Furthermore, the influence of NAD1 repletion on
mice with preexisting liver hyperlipidemia and aberrant
lipid metabolism has yet to be determined.
Several approaches have been recently explored to ele-
vate NAD1 levels in vivo. This includes the use of natural
NAD1 precursors, such as nicotinamide riboside (NR),
that are readily converted into bioavailable NAD1 in
metabolic tissues after dietary administration.16 In addi-
tion to NR, there are three other molecules described as
root substrates for mammalian NAD1 biosynthetic path-
ways, including tryptophan, niacin, and nicotinamide.15
Once NR is transported into cells by nucleoside trans-
porters,17 it is phosphorylated by NR kinases 1 and 2.18
Phosphorylation of NR generates nicotinamide mononu-
cleotide (NMN), an intermediate compound of NAD1
biosynthesis, which can also be intraperitoneally adminis-
tered to animals to increase tissue NAD1 levels.11 This
metabolite can then be converted to NAD1 through the
action of NMN adenylyltransferase.
In this study, we demonstrate that a Western diet,
including high levels of fat and sucrose, could induce dys-
function in hepatic NAD1 homeostasis and contribute to
the development of NAFLD, and that NAD1 repletion by
feeding animals with a diet enriched in NR may prevent or
reverse NAFLD by inducing the mitochondrial unfolded
protein response (UPRmt) to elicit a mitohormetic
response. We further confirmed that NAD1 repletion can
reverse liver mitochondrial dysfunction in HFC-fed Apoe2/
2mice, another well-known model of NAFLD.19
Materials and Methods
Animal Experiments. Male C57BL/6J mice were
purchased from Charles River Laboratories (Wilming-
ton, MA) and were housed under a 14 hour light, 10-
hour dark cycle at 21-238C and had ad libitum access to
water and food throughout the experiment. From the
age of 8 weeks, mice were separated into four groups of
10 animals. Animal cohorts were fed either a Western
high-fat and high-sucrose (HFHS) diet with 44.6% of
kcal derived from fat (of which 61% is derived from sat-
urated fatty acids) and 40.6% of kcal derived from car-
bohydrates (primarily sucrose 340 g/kg diet)
(TD.08811, 45% kcal Fat Diet; Harlan Laboratories
Inc., Madison, WI)20 or normal chow diet (CD). NR-
treated animals were fed with pellets containing vehicle
(double-distilled water; ddH20) or NR (400 mg/kg/day)
for 2, 9, or 18 weeks. All animal experiments were
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carried according to national Swiss and European Union
ethical guidelines and approved by the local animal
experimentation committee of the Canton de Vaud
under license #2465.
Generation of Sirt1L2/L2 mice has been previously
described.21 Liver-specific Sirt1 knockout mice were
generated by breeding Sirt1L2/L2 mice with mouse albu-
min (Alb)-Cre mice (AlbcreTg/0),22 both of which have
been backcrossed to C57BL/6J mice for 10 generations.
These mice lines were then further intercrossed to gener-
ate mutant AlbcreTg/0/Sirt1L2/L2 mice, which were
termed Sirt1hep2/2 mice. The following Sirt1hep2/2 and
Sirt1L2/L2 mice were fed with HFHS pellets containing
vehicle (ddH20) or NR (400 mg/kg/day) for 14 weeks.
Six-week-old male Apoe2/2 mice were purchased from
The Jackson Laboratory (Bar Harbor, ME) and randomly
assigned to modified AIN-93M diets (Dyets, Inc., Bethle-
hem, PA) that included low-fat (Apoe2/2/LF), high-fat and
high-cholesterol (Apoe2/2/HFC), and HFC supplemented
with NR (Apoe2/2/NR-Ther; see Supporting Table 1).
Seven-week-old mice were placed on either LF (4% fat by
weight) or HFC (22% fat, 0.2% cholesterol by weight)
diets for 3 weeks to induce aberrant lipid metabolism. At 10
weeks of age, 500 mg/kg/day (mpk) of NR was supple-
mented to the assigned HFC diet group for 7 weeks. All
procedures concerning Apoe2/2mice were approved by the
Animal Care and Use Committee at the University of Con-
necticut (Storrs, CT).
The procedures used for NR food preparation, along
with in vivo mouse phenotyping and sacrifices, are
described in the Supporting Methods.
Primary Hepatocytes. Primary hepatocytes from
Sirt1 floxed (Sirt1L2/L2) or Sirt3 floxed (Sirt3L2/L2) mice
(described in previous studies21,23, respectively) were iso-
lated with Liberase Blendzyme (Roche Diagnostics, India-
napolis, IN) perfusion as described previously, with minor
modifications.24 Isolated hepatocytes were then plated in
Dulbecco’s modified Eagle’s medium (4.5 g/L of glucose;
Gibco, Gaithersburg, MD) with 10% fetal bovine serum
and penicillin and streptomycin and maintained at 378C
in a 5% CO2 atmosphere. Four hours after plating, cells
were transduced with adenovirus expressing green fluores-
cent protein (Ad-GFP) or Cre recombinase (Ad-Cre) at a
multiplicities of infection 5 5 to generate matched Sirt12/
2 or Sirt32/2 (loss-of-function) and Sirt1L2/L2 or Sirt3L2/L2
wild-type hepatocytes, respectively. Hepatocytes were then
incubated overnight before changing media. Primary hepa-
tocytes were then treated with 1 mM of NR or vehicle
(ddH20) for 24 hours.
Histology and Liver Function. Preparation of his-
tological tissue sections, staining procedures for hematox-
ylin and eosin (H&E), Oil Red O, Picrosirius red,
cytochrome c oxidase activity, succinate dehydrogenase
activity, CD45, Masson’s trichrome, and blinded scoring
for steatosis are described in the Supporting Methods.
Mitochondrial function in fresh liver tissue was evaluated
with high-resolution respirometry and citrate synthase
activity, as also described in the Supporting Methods.
Quantification of NAD1 and Adenosine Triphos-
phate Levels. NAD1 was extracted using acidic and
alkaline extraction methods, respectively. Tissue NAD1
was analyzed with mass spectrometry, as previously
described.25 Total adenosine triphosphate (ATP) content
was measured by the CellTiter-Glo luminescent cell via-
bility assays (Promega). Typically, luminescence was
recorded with a Victor X4 plate reader (PerkinElmer,
Waltham, MA), and values were normalized by the total
protein concentration, determined using a Bradford assay.
Liver Triglyceride, Cholesterol, and LPO Measure-
ments. Hepatic lipids were extracted as performed
previously.24 Triglyceride (TG) and cholesterol contents
in hepatic lipid fractions were quantified using enzy-
matic assays (Roche). The by-product of LPO and a
marker of oxidative stress, 4-hydroxynonenal (HNE),
was measured following the manufacturer’s protocol of
the OxiSelect HNE-His Adduct enzyme-linked immu-
nosorbent assay Kit (Cell Biolabs Inc., San Diego, CA).
Identification of Transcript Correlations in Mice
and Humans. Liver microarray data (Affymetrix
Mouse Gene 1.0 ST) from a BXD mouse genetic refer-
ence population26 were analyzed for transcript expres-
sion correlations between NAD1 regulating and b-
oxidation genes using the GeneNetwork program
(http://www.genenetwork.org). Raw microarray data are
also publicly available on Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo) under the
accession number GSE60149. Similarly, human micro-
array data were retrieved from the GSE4865427 and
GSE958828 GEO data sets.
Transcript and Protein Expression. Real-time
quantitative polymerase chain reaction (qPCR), mito-
chondrial DNA (mtDNA) content, western immuno-
blotting, and blue native polyacrylamide gel
electrophoresis (PAGE) techniques are described in the
Supporting Methods.
Statistical Analysis. Statistical analysis was per-
formed with Prism Software (version 6.0; GraphPad Soft-
ware Inc., La Jolla, CA). The significance of differences
between two groups was determined by unpaired two-tailed
Student t test. For comparison of multiple groups, we
applied a one-way analysis of variance (ANOVA) with a
post-hoc Bonferroni test. Results are presented as mean 6
standard error of the mean (SEM). A P value <0.05 was
considered significant.
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Results
Regulation of NAD1 Homeostasis and Lipid
Metabolism. Exploring the potential for NAD1 dys-
function in the development and progression of
NAFLD, we first evaluated gene expression patterns
related to NAD1 homeostasis and lipid metabolism in
two separate existing liver tissue data sets that include
22127 and 42728 normal human samples. These data
sets conveyed a positive correlation between custom-
designed gene sets for b-oxidation and genes involved in
NAD1 biosynthesis (Fig. 1A,C). Specifically, transcripts
for nicotinamide phosphoribosyltransferase, the rate-
limiting enzyme for NAD1 salvage from nicotinamide,
and NRK1 correlated positively to b-oxidation genes,
Fig. 1. NAD1 regulating enzymes and NAD1 levels correlate with lipid metabolism in both humans and mice. Transcripts from NAD1-synthesis
genes (shown in blue font), in contrast to NAD1-consuming genes (shown in red font), were positively correlated with regulators of b-oxidation using
custom-designed data sets derived from (A) two human data sets, including 42728 and 22027 human liver samples or (B) two mouse data sets,
including 42 BXD strains fed either chow or high-fat diets.9,26 As seen on a correlogram, blue correlations are positive (red correlations are nega-
tive—intensity of the colors correlates with level of significance). NRK1 and NAMPT transcripts, in contrast to Parp1, were positively correlated to
mitochondrial b-oxidation genes, ACADL, ACADM, and HADH, in data sets from 42728 and 22027 human liver samples (C) or 42 BXD strains fed
either chow or high-fat diets.9,26 (D) Consistent with these findings in mice and humans, we see reductions in (E) hepatic NAD1 levels, followed by
increases in (F) hepatic TG levels, in mice fed 9-18 weeks with a HFHS diet (n 5 5-10). **P < 0.001; ***P < 0.0001 compared to the CD
cohort. Data are expressed as mean 6 SEM. One-way ANOVA with a post-hoc Bonferroni test was used for all statistical analyses.
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suggesting a beneficial effect of NAD1 synthesis on
NAFLD. In contrast, negative correlations were
observed when compared to NAD1 consumers, such as
poly adenosine diphosphate (ADP)-ribose (PAR) poly-
merase 1 (PARP1), and the cyclic ADP-ribose synthase,
CD38. These correlations were conserved in livers of
genetically diverse strains of mice from the BXD genetic
reference population fed either chow or high-fat diets
(described in previous works9,26; Fig. 1B,D). A unique
custom-designed gene set was also created for the com-
parison of matching genes between the human and
mouse data sets (Supporting Fig. 1A). To experimentally
corroborate this link observed in human and mice, we
examined a mouse model of NAFLD.20 Mice given an
HFHS diet displayed a progressive loss of liver NAD1
levels that was matched by step-wise increases in liver
TG levels, linking changes in NAD1 homeostasis to
liver metabolism (Fig. 1E,F). Thus, NAD1 regulating
enzymes, reflecting more NAD1 availability, appear to
correlate with lipid metabolism in both human and
mouse liver samples.
NAD1 Repletion, as a Therapeutic Treatment, Can
Revert Indications of NASH in HFHS-Fed Mice. To
evaluate the potential of NAD1 repletion to protect
mice from the development of NAFLD, we compared
7-week-old mice exposed to 18 weeks of HFHS diet to
mice given the same diet supplemented with NR (400
mg/kg/day) from the onset of the HFHS diet (preven-
tion mode) or 9 weeks after the start of the diet
(therapeutic/intervention mode; Fig. 2A). Importantly,
both preventive and therapeutic approaches improved
glucose tolerance (Fig. 2B,C) and insulin sensitivity
(Fig. 2D) with concurrent reductions in body weight
(Fig. 2E) and fat mass (Fig. 2F), each being frequently
measured as secondary outcomes in NAFLD-related
clinical trials.
NR boosted whole-liver lysate and mitochondrial
NAD1 levels in HFHS-fed animals from both cohorts,
with each cohort consuming similar quantities of food
(Fig. 3A). As a result, plasma elevations in alanine ami-
notransferase (ALT) and aspartate aminotransferase
(AST), indicators of liver damage, induced by an HFHS
diet, were completely attenuated with NR (Fig. 3B).
Hepatic TG, cholesterol, and LPO levels were also
reduced upon NR administration (Fig. 3B). Remark-
ably, the 9-week intervention, similar to the 18-week
preventive treatment, reversed changes in liver weight
that occurred after HFHS diet (Fig. 3C), indicating that
even therapy initiated after the onset of disease was ben-
eficial. Furthermore, NR improved liver H&E histology
scores for severity and extension of steatosis (Fig.
3C,D). Indications for increased lipid use with an
Fig. 2. Glucose intolerance and NAFLD-induced insulin sensitivity are reversed with NAD1 repletion. Phenotyping was performed on CD, HFHS,
NR-Prev, and NR-Ther cohorts after 5-18 weeks of treatment (NR dose: 400 mg/kg/day). (A) Schematic illustrating the three experimental groups;
animals starting on an HFHS diet at 7 weeks of age are given NR in a preventive (NR-Prev) mode for 18 weeks or 9 weeks in a therapeutic
approach (NR-Ther). Mice were sacrificed after a 4-hour fast. The control chow-diet regimen is not shown on the schematic. NR improved (B) glu-
cose handling and (C) plasma insulin levels after an oral glucose tolerance test (OGTT; insets show the area under the curve [AUC]), measured
after 15 weeks of diet (n 5 5; chow-diet regimen is not shown). NR also (D) improved insulin sensitivity during an insulin tolerance test (ITT),
measured after 17 weeks of diet (n 5 5; chow-diet regimen is not shown) [Correction added February 3, 2016, after first online publication:
“(mg/ml)” in Y axis of Fig. 2D was changed to “(mg/dl).”] and (E) reduced body weight (n 5 8-10). Both cohorts treated with NR exhibited lower
(F) whole-body fat mass, as measured by echo magnetic resonance imaging after 18 weeks of diet, and epididymal fat mass at sacrifice, com-
pared to the HFHS cohort (n 5 8-10). *P < 0.05; **P < 0.001; ***P < 0.0001 compared to the HFHS cohort. Data are expressed as mean
6 SEM. One-way ANOVA with a post-hoc Bonferroni test was used for all statistical analyses. Male mice were used for these experiments.
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NR-supplemented diet was evident after just 5 weeks of
treatment, with reductions in the respiratory exchange
ratio during the dark and light cycles (Supporting Fig.
2A-C). The development of a pale white liver color,
which occurs with increased lipid content or steatosis,
was attenuated by NR and was corroborated by reduced
staining with Oil Red O for lipid content (Fig. 3D). NR
also reduced hepatic fibrosis, as indicated by less Picro-
sirius red and Masson’s trichrome staining (Fig. 3D and
Supporting Fig. 3), substantiated by reduced transcript
expression of Col, Fn1, and Acta2 (Fig. 3E). In line with
this, although the observations were not linked to
NAD1 metabolism, inhibition of PARP, a major con-
sumer of NAD1, was shown to protect against chemi-
cally induced liver fibrosis.29 In parallel, in NR-treated
animals, there was a reduction in the HFHS-induced
liver transcripts of the peroxisome proliferator-activated
receptor (Ppar)c, a mediator of lipogenesis30 (reviewed
in a previous work31), resulting in the reduction of
Srebf1, Acc, Fasn, and Scd1 messenger RNAs (mRNAs;
Fig. 3E). NR treatment also lowered the expression of
genes involved in lipid uptake (Cd36), TG formation
(Dgat1), and packaging for lipoprotein secretion (Cideb,
Apob; Fig. 3E). In agreement with the NR-mediated
improvements in liver health and lipid content, there
was also a reduction in the hepatic expression of inflam-
matory transcripts Tnfa, Mcp, Vcam, Il-6, and Il-1b
(Fig. 3E). These observations were complimented by the
attenuation of plasma tumor necrosis factor alpha
(TNF-a) levels (Fig. 3F) and the reduced infiltration of
CD45-positive leukocytes into the liver with NR treat-
ment (Supporting Fig. 3).
Fig. 3. NAD1 repletion protects and reverses the development of NAFLD in HFHS-fed mice. Phenotyping was performed on CD, HFHS, NR-
Prev, and NR-Ther cohorts following 9-18 weeks of treatment (NR dose: 400 mg/kg/day). (A) After sacrifice, we noted that NR elevated hepatic
whole-tissue and mitochondrial NAD1 levels, with each cohort having consumed similar amounts of food (n 5 8-10). (B) NR reduced circulating
ALT and AST, indicators for liver damage (n 5 8-10), and improved liver TG and cholesterol accumulation and LPO (n 5 5). (C) NR lowered liver
weight (n 5 8-10) and blinded H&E scores for severity and extension of steatosis. (D) Matching images of representative livers and liver sec-
tions stained with H&E, Oil Red O (lipid content appears red), and picrosirius red (liver fibrosis represented by collagen stained red) (n 5 4-5)
are also represented. (E) These functional and morphological changes are supported by the relative expression of genes associated with fibrosis,
lipogenesis, lipid metabolism, and inflammation (n 5 6). (F) Preventive and therapeutic treatments also attenuated HFHS-induced levels of
plasma TNF-a. *P < 0.05; **P < 0.001; ***P < 0.0001 compared to the HFHS cohort. Data are expressed as mean 6 SEM. One-way
ANOVA with a post-hoc Bonferroni test was used for all statistical analyses. Male mice were used for these experiments.
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NR Therapy Reverses HFHS-Induced Mitochon-
drial Dysfunction and Increases Transcripts for b-
Oxidation. Development of NAFLD, and the ensu-
ing progression of liver cirrhosis, relies mainly on abnor-
mal liver lipid accumulation. Whereas increased lipid
uptake and lipogenesis can lead to NAFLD, incomplete
FA oxidation in the context of mitochondrial dysfunc-
tion also contributes to hepatic FA and lipid over-
load20,32 (reviewed in a previous work6). Although NR
has been demonstrated to prevent diabesity in HFD-fed
animals,16 the ability of NAD1 repletion to reverse liver
damage, brought on by mitochondrial dysfunction, has
yet to be shown. Here, we demonstrate an improvement
in liver mitochondrial function following NR, with
increased citrate synthase (CS) activity and oxygen con-
sumption rates (OCRs) driven by complex I (and trend-
ing with complex II) in the presence of ADP (Fig.
4A,B). Additionally, cytochrome c oxidase (COX) and
Fig. 4. Treatment with NR increases liver tissue respiratory capacity ex vivo and b-oxidation gene expression. Measurements were performed
on liver samples from CD, HFHS, NR-Prev, and NR-Ther cohorts after 9-18 weeks of treatment (NR dose: 400 mg/kg/day) and are represented
as fold changes compared to the HFHS group. NR increased (A) citrate synthase activity, (B) basal OCR and CI-coupled driven OCR, in the pres-
ence of glutamate, pyruvate, malate, and ADP, but was not significant for CII-coupled driven OCR, in the presence of succinate, although a trend
was noted (n 5 6). (C) Histological sections show improvements in both COX and SDH activities in NR-treated groups compared to HFHS-fed
mice (n 5 4), culminating in the attenuation of the decline in (D) ATP levels (n 5 5). (E) Increases were observed for mRNA transcript levels of
genes regulating mitochondrial biogenesis, Ppara and Ppard/b, and genes regulating b-oxidation (n 5 6). (F) Liver gene transcript expression
measurements were performed for Sirt1, Pgc-1, and genes associated with b-oxidation and lipogenesis in mice given 2 weeks of an HFHS or
HFHS-NR diet (NR dose: 400 mg/kg/day). Starting at 8 AM, mice were fasted for 24 hours or fasted for 18 hours and refed for 6 hours. Data
are represented as fold changes compared to the fasted CD group. For panels A, B, D and E: *P < 0.05; **P < 0.001; ***P < 0.0001 com-
pared to the HFHS cohort and P < 0.05 compared to the CD cohort. For panel F: P < 0.05, overall effect of treatment versus control mice;
‡P < 0.05, interaction of each treatment versus control mice. Data in all panels are expressed as mean 6 SEM. One-way ANOVA with a post-
hoc Bonferroni test was used for statistical analyses of panels A, B, D, and E. Two-way ANOVA with a post-hoc Holm-Sidak test was used for sta-
tistical analysis of panel F. Male mice were used for these experiments.
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succinate dehydrogenase (SDH) activity was enhanced in
liver sections after NR (Fig. 4C). Changes in citrate cycle
activity and oxidative phosphorylation (OXPHOS) with
NR led to a recovery in liver ATP concentrations com-
pared to mice fed only an HFHS diet (Fig. 4D). These
functional changes are supported by NR-induced
increases in transcripts for Nampt, Sirt1, Nrf1, and Tfam,
as regulators of mitochondrial biogenesis (Fig. 4E).
mRNA levels of Ppara and Ppard/b, transcriptional acti-
vators of genes involved in b-oxidation and which protect
against NAFLD,32-34 showed trends of reduction with an
HFHS diet and recovery with NR (Fig. 4E). To analyze
how PPARa, the predominant PPAR isoform in hepato-
cytes, contributes to the beneficial effects of NR on b-
oxidation and mitochondria biogenesis, we exposed
AML12 hepatoma cells to small interfering RNA for
Ppara (Supporting Fig. 4). NR treatment of AML12 cells
did not increase transcript levels of Ppara, yet upon
knockdown of Ppara, expression of Sirt1 showed a tend-
ency towards reduction along with the significant attenu-
ation of the stimulatory effects of NR on b-oxidation
genes, such as Mcad and Acox1, and the expression of
Tfam, a crucial transcription factor for mitochondrial
genes. Therefore, NR lost some of its ability to enhance
b-oxidation and mitochondrial function when Ppara was
absent.
To investigate whether it was changes in b-oxidation
or lipogenesis that initially led to the NR-mediated
reduction of liver steatosis, we compared the activation of
genes associated with b-oxidation or lipogenesis in NR-
treated mice fed an HFHS diet for a short 2-week period,
to avoid the confounding changes in mouse body weight
observed after long-term HFHS diets. After 2 weeks of
diet, NR treatment accentuated the elevation in tran-
scripts for b-oxidation genes after 24 hours of fasting
(Fig. 4F). In contrast, no difference in transcripts of lipo-
genesis genes were found in refed NR-treated animals.
Consequently, in our long-term studies, NR-mediated
reductions in lipogenesis transcripts (Fig. 3E) were not
caused by the active repression of lipogenesis genes.
Therefore, functional and molecular improvements in
b-oxidation and OXPHOS upon NR treatment, instead
of reduced lipogenesis, are responsible for the attenuation
of NAFLD in HFHS animals and support the hypothesis
that NAD1 repletion protects and enhances liver mito-
chondria during periods of FA overload.
NAD1 Repletion Prompts Mitonuclear Protein
Imbalance, Inducing the UPRmt Markers CLPP and
HSP10 In Vivo, While Reducing Endoplasmic Retic-
ulum Stress. Next, we examined whether the severe
hepatic lipid accumulation and respiratory defects that
were improved by NR administration were the result of
changes in mitochondrial content, complex formation,
and UPRmt signaling. Recently, sirtuin-dependent mito-
chondrial changes were shown to rely, in part, on induc-
tion of UPRmt, triggered by an imbalance in
mitochondrial- versus nuclear-encoded mitochondrial pro-
teins.21,35 This mitonuclear imbalance activates a retro-
grade signal that induces a mitohormetic and adaptive
nuclear response, ultimately repairing and improving mito-
chondrial function. These mitohormetic signals can
attenuate the harmful repercussions of aging, inherited
mitochondrial diseases, or a high-fat diet on whole body
metabolism.9,21,36 mtDNA abundance was elevated along
with mitochondrial complexes and supercomplexes, as
demonstrated by qPCR and blue native PAGE analyses
(Fig. 5A,B). Interestingly, the protein ratio between
SDHB, encoded by nuclear DNA (nDNA), and
MTCO1, which is encoded by mtDNA, was reduced after
NR treatment, reflective of a mitonuclear protein imbal-
ance (Fig. 5C) and reminiscent to similar changes in mito-
nuclear protein imbalance that we reported in other model
systems (Caenorhabditis elegans21 and muscle9) with
NAD1 boosting strategies. Mitonuclear protein imbalance
has previously been shown to trigger the UPRmt.35 In line
with this premise, protein and transcript levels of CLPP
and HSP10 (Hspe1), two UPRmt biomarkers,9,21 were ele-
vated in mice treated with NR (Fig. 5D). In contrast to
NR-induced UPRmt, NR reduces endoplasmic reticulum
(ER) stress. In fact, an ER-specific unfolded protein
response (UPRer) is activated during liver steatosis and
occurs in NAFLD, viral hepatitis, and alcohol-induced
liver injury (reviewed in 37). Persistent activation of UPRer
can cause ER stress-dependent alterations in lipid homeo-
stasis and is suggested to contribute to steatosis. The activa-
tion of UPRer was confirmed in HFHS-fed animals by
qPCR, demonstrating increased expression of the tran-
scription factor, activating transcription factor 4 (ATF4),
which transactivates the promoter of the binding immuno-
globulin protein/glucose-regulated protein 78 (GRP78)
and the CCAAT/enhancer-binding protein homologous
protein, a proapoptotic transcription factor (Fig. 5E). Also,
at the protein level, ATF4 and GRP78 were induced (Fig.
5E). These transcript and protein markers of UPRer activ-
ity were all reduced after both NR treatment regimens
(Fig. 5E).
In Vivo UPRmt-Dependent Activation of Mito-
chondrial Biogenesis Requires SIRT1. Furthermore,
we set out to determine whether NAD1 repletion in
hepatocytes triggers mitochondrial improvements
through a SIRT1- and/or SIRT3-dependent activation
of UPRmt, as reported previously.21,38 Treatment of pri-
mary hepatocytes with NR induced an elevation in
NAD1 levels and mtDNA abundance, similar to the
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effect observed in vivo (Fig. 6A). The SIRT1-
dependency of NR-induced mitochondrial biogenesis
was first demonstrated in AML12 cells using the SIRT1
inhibitor, EX527 (Fig S5A). Moreover, primary hepato-
cytes from Sirt1L2/L2 mice, infected with an Ad-GFP
(control) or Ad-Cre to induce a Sirt1 loss of function
(LOF), showed a clear SIRT1-dependent reduction in
the ratio of the nuclear-encoded SDHB and
mitochondrial-encoded MTCO1 proteins (SDHB/
MTCO1) resulting in a mitonuclear imbalance, which
together with the elevation of HSP10, HSP60, and
CLPP (data not shown), is indicative of the UPRmt (Fig.
6B). In addition to the Sirt1 LOF, which completely
attenuated the UPRmt induction, we observed an analo-
gous, but less robust, effect on primary hepatocytes with
a Sirt3 LOF (Supporting Fig. 5B). Thus, the mitonu-
clear imbalance and activation of UPRmt, observed after
boosting NAD1 levels in liver cells, are reliant on the
presence of either SIRT1 or SIRT3. We next evaluated
the possible cell-autonomous contribution of SIRT1 in
hepatocytes in mediating the effects of NR using a liver-
specific SIRT1-deficient mouse line (Sirt1hep2/2). In
these Sirt1hep2/2 mice, the effect of NR on body and
liver weights after 14 weeks on an HFHS diet were non-
significant (Fig. 6C). This was matched by the reversal
of the NR-mediated benefits in liver TGs and lipids in
Sirt1hep2/2 mice (Fig. 6D,E). These results are further
corroborated by clear reductions in NR’s efficacy to
induce expression of mitochondrial- and b-oxidation-
associated genes (Fig. 6F). These data demonstrate that
although NR may have some systemic effects that ameli-
orate the impact of an HFHS diet, SIRT1 in hepato-
cytes is essential for NR-mediated liver benefits.
Reversal of Tissue Steatosis in the Apoe2/2 Mouse
Model of NAFLD is NAD1-Dependent. To confirm
the beneficial effects of NR, we repeated several pheno-
typing experiments on HFC-fed Apoe2/2 mice. Apoe2/2
mice were challenged with 3 weeks of HFC diet, then
Fig. 5. Improvements in mitochondrial function driven by NAD1 and UPRmt induction and UPRer attenuation in vivo. (A) Mitochondrial abun-
dance was higher in livers from mice treated with NR. Results are expressed as mtDNA amount (Cox2) relative to nDNA (Hk2) (n 5 6). (B) This
was matched by increases in mitochondrial complexes and supercomplexes, as evidenced by blue native PAGE of isolated liver mitochondria.
(C) NR induced a mitonuclear protein imbalance, indicated by the reduced ratio between SDHB (nuclear encoded complex II protein) and
MTCO1 (mtDNA encoded complex IV protein) expression, from whole-liver extracts. (D) Activation of UPRmt by NR is demonstrated by increases
in hepatic gene transcripts for Clpp and Hspe1 (HSP10), but not Hspd1 (HSP60) (n 5 6). These are matched by elevations in CLPP and HSP10
protein levels and the mitochondrial proteins, ATP5A and UQCRC2, from isolated liver mitochondria, indicating higher expression of oxidative
phosphorylation proteins per amount of mitochondria. (E) HFHS diet-induced transcripts involved in the UPRer, including atf4, chop, and grp78,
were mostly reduced after NR treatments, as confirmed with ATF4 and GRP78 protein expression analysis. *P < 0.05; **P < 0.001, compared
to the HFHS cohort, and P < 0.05 compared to the CD cohort. Data are expressed as mean 6 SEM. One-way ANOVA with a post-hoc Bonfer-
roni test was used for all statistical analyses. Male mice were used for these experiments.
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treated (in a therapeutic mode) with an HFC diet sup-
plemented with NR for another 7 weeks (Apoe2/2/NR-
Ther). Similar to HFHS-fed C57BL/6J mice, HFC-fed
Apoe2/2 mice treated therapeutically with NR exhibited
increased hepatic NAD1 levels and reductions in body
weight (Fig. 7A,B), circulating ALT, and total hepatic
cholesterol and TG levels (Fig. 7C). NR also reduced
hepatosteatosis in this model, as observed with H&E
staining, which was not dependent on food intake (Fig.
7D; HFC cohorts). However, given that liver weight
and epididymal fat mass did not increase in Apoe2/2
mice fed an HFC diet, there was no strong reduction in
these parameters with NR (Fig. 7E). Yet, there was a
trending increase in mtDNA abundance with NR treat-
ment, which is consistent with increases in Sirt1, Tfam,
and b-oxidation gene expression (Fig. 7F). Thus, NR
Fig. 6. NR-mediated liver benefits arise from liver-specific SIRT1-dependent activation of UPRmt retrograde signaling. Primary hepatocytes cells
treated with NR (1 mM; 24 hours) show increased (A) cellular NAD1 levels and mitochondrial abundance. (B) NR treatment of Sirt1L2/L2 hepato-
cytes infected with an adenovirus expressing Cre attenuated mitochondrial protein expression and mitonuclear imbalance (SDHB/MTCO1 ratio)
upon Sirt1 LOF. Increases in HSP10 are also shown to be dependent on SIRT1. (C) Body-weight change, liver weight, and (D) liver TG levels in
liver-specific Sirt1hep2/2 and SirT1L2/L2 mice fed an HFHS diet with NR for 14 weeks. (E) Images of representative liver sections stained with Oil
Red O (n 5 5). (F) Relative changes in transcript levels of genes associated with mitochondrial biogenesis and b-oxidation (n 5 5) in mice of
the indicated genotypes. *P < 0.05; **P < 0.001; ***P < 0.0001 compared to the HFHS cohort. P < 0.05, overall effect of treatment
versus control mice; ‡P < 0.05, interaction of each treatment versus control mice. Data are expressed as mean 6 SEM. Two-way ANOVA
with a post-hoc Holm-Sidak test was used for statistical analyses of panels B, C, D and F. Student t test was used for the statistical analysis of
panel A. Male mice were used for these experiments. Abbreviation: Veh, vehicle.
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used as a therapeutic treatment consistently reverses
indications of liver damage and mitochondrial dysfunc-
tion between two well-known models of NAFLD in
mice.
Discussion
Although NAFLD is thought to arise from an imbal-
ance between lipid uptake/synthesis and lipid oxidation/
export in hepatocytes,6 relatively little is known about the
role of mitochondria in this process. NAD1-mediated
changes in sirtuin deacetylase activity have been previ-
ously associated with induction of expression of genes
and activation of proteins linked to improved mitochon-
drial function (reviewed in a previous work39). Support-
ing the importance of NAD1 in liver metabolism, we
discovered a striking negative correlation between tran-
scripts of NAD1-consuming genes, such as Cd38 and
Parp1, and those involved in b-oxidation in liver biopsies
from two large human cohorts and in livers from the
mouse BXD genetic reference population. In contrast,
NAD1 salvage enzyme transcripts, such as Nrk1 and
Nampt, were positively correlated to matching gene sets
for b-oxidation in mice and humans. Correspondingly,
mice that were fed a HFHS diet exhibited a progressive
decline in liver NAD1 levels that were matched by an
increased liver TG content. Overall, these findings dem-
onstrate a conserved link in humans and mice between
expression of NAD1 consumption/biosynthesis genes
and genes that regulate b-oxidation in the liver.
From these data, we postulated that by boosting
NAD1 levels in long-term HFHS-fed animals, we could
Fig. 7. Liver damage in Apoe2/2 mouse model of NAFLD was reversed by NAD1 repletion. Apoe2/2 mice were fed either a low-fat diet
(Apoe2/2/LF) or given an HFC diet for 3 weeks that was either continued to induce NAFLD (Apoe2/2/HFC) or supplemented with NR (Apoe2/
2/NR-Ther) for another 7 weeks (NR: 500 mg/kg/day). Mice were sacrificed after overnight fasting. (A) NR elevated hepatic NAD1 levels result-
ing in (B) reduced body weight. Elevated NAD1 levels reduced (C) circulating ALT, an indicator for liver damage (n 5 8-10), and improved
hepatic cholesterol and TG accumulation. (D) NR led to less steatosis, as observed by H&E-stained liver sections (n 5 8-10), with similar food
intake between HFC-fed animals (n 5 8-10). (E) NR showed a trend to reduce liver and epididymal fat pad weights. This resulted in (F) a trend
to increase mtDNA abundance and in a significant elevation of the relative expression of genes associated with mitochondrial biogenesis and b-
oxidation after NR (n 5 8-10). *P < 0.05; **P < 0.001; ***P < 0.0001 compared to the HFHS cohort. Data are expressed as mean 6
SEM. One-way ANOVA with a post-hoc Bonferroni test was used for all statistical analyses. Male mice were used for these experiments.
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increase sirtuin-mediated UPRmt activation and mito-
chondrial biogenesis, while also reducing UPRer stress
response. In agreement, NR attenuated the severe mito-
chondrial dysfunction, typified by reduced mitochon-
drial content and function, present in fatty livers of
mice fed a long-term HFHS diet. These robust effects
of NR on mitochondrial function were reliant on the
NAD1-mediated SIRT1 and SIRT3 induction of mito-
nuclear protein imbalance, triggering the UPRmt. Simi-
lar to previous reports linking the beneficial effects of
NR to the UPRmt,9,14,21,38,40,41 activation of UPRmt in
livers of these NR-treated animals maintained optimal
mitochondrial function despite a chronic FA overload.
Interestingly, NAD1 metabolism also appears to play a
central role in alcohol-mediated liver damage,42 leading
us to postulate that a proper NAD1 balance is essential
for maintaining liver homeostasis.
Boosting NAD1 levels, by using NR as a preventive
strategy, proved to avert the onset of NAFLD, indicating
that this vitamin B3 analog has potential as a nutraceuti-
cal or food supplement to protect liver function. More
relevant for a therapeutic setting was our observation that
NR administration was able to attenuate mitochondrial
dysfunction and liver damage in mice with established
NAFLD, as supported by the improvement of primary
and secondary indicators of NAFLD. The therapeutic
effect of NR was further confirmed in our study of
Apoe2/2 mice challenged with an HFC diet, as an inde-
pendent model of NAFLD that is less dependent on
changes in body mass. Importantly, using Sirt1hep2/2
mice, we demonstrate that the beneficial effect of NR on
NAFLD is reliant on a nonsystemic component driven
by activation of SIRT1 specifically in hepatocytes.
Therefore, our results indicate that NAD1 repletion
prevented or reversed the phenotypes associated with
NAFLD, such as liver lipid accumulation, liver fibrosis,
and the NAFLD molecular signature typified by increased
PPARc mRNA levels and its downstream transcripts
linked to lipogenesis. However, the reduction in the activa-
tion of lipogenesis genes was shown to be secondary to
mitochondrial activation and enhanced b-oxidation and
OXPHOS. In parallel to the reversal of lipid accumulation
and fibrosis, there were also significant reductions in liver
and plasma inflammatory markers associated with
NAFLD. Future work should examine how chronic lipid
overload and the ensuing inflammation, a process associ-
ated with PARP activation (reviewed in a previous
work43), are linked to the reduction in liver NAD1 levels.
In combination, our data show that the replenish-
ment of depleted liver NAD1 stores in mouse models of
NAFLD, by administration of NR supplements, recov-
ers liver NAD1-dependent SIRT1 and SIRT3 signaling
to counteract the development of NAFLD. These bene-
ficial effects of NR are largely mediated by the cell-
autonomous effect of SIRT1 activation in the liver. Fur-
thermore, our bioinformatics data suggest that reduced
NAD1 stores may also be a hallmark of human NAFLD
and NASH, warranting further exploration of NAD1
replenishing strategies to treat these pervasive liver
diseases.
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